Mitokinin, Inc.
USPTO PatentsView assignee record - 5 granted patents across 3 technology areas, recorded in grant years 2019–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).
The verdict
According to USPTO PatentsView, Mitokinin ranks #48,793 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 3 technology areas.
- #48,793
- of 49,997 US assignees by volume
- 16th percentile
- by Innovation Score (24.8/100)
- 13.4
- avg claims per patent
- +300%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R48793 · US Corporation #48,793 · 5 grants
GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL
- GRANTS-MICRO 5 grants
- BOTTOM-DECILE #48,793/49,997
- PHOTO-FINISH Miraculum
- CPC-NARROW C07D · 3 areas
- INNOV-THIN 24.8/100
- CLAIMS-RICH 13.4 claims/avg
- TYPE-USCORP US Corporation
- VEL-SURGE +300% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Miraculum, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Mitokinin’s 24.8 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Mitokinin
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Mitokinin · this assignee 25
Mitokinin · this assignee
25 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Mitokinin's Innovation Score is 24.8/100 (16th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Mitokinin?
Each dot is one of Mitokinin’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Mitokinin’s own 13.4 claims/patent is ABOVE the 11.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Mitokinin's grants concentrate
Mitokinin, Inc. is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2020 (2 grants) versus a trough of 1 in 2019. By volume, Mitokinin sits between Miraculum, Inc. and Mobile Acuity Limited.
Mitokinin's three-year grant acceleration
Mitokinin, Inc. shows 2 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Mitokinin's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Miraculum
Miraculum, Inc.
5 patents
- Mircon Technology
Mircon Technology, Inc.
5 patents
- Mironid
Mironid Limited
5 patents
- Misfit
Misfit, Inc.
5 patents
- Mitsubishi Chemic…
Mitsubishi Chemical Cleansui Corporation
5 patents
- Momelan
MoMelan Technologies, Inc.
5 patents
- Mobi
Mobi, LLC
5 patents
- Mobile Acuity
Mobile Acuity Limited
5 patents
- Mitokinin ◀
Mitokinin, Inc.
5 patents
What this shows Mitokinin holds 5 patents at rank #48,879, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Mitokinin
By rank, the assignees closest to #48,879 in granted patent volume.
- Miraculum, Inc. #48,875 · 5 patents
- Mircon Technology, Inc. #48,876 · 5 patents
- Mironid Limited #48,877 · 5 patents
- Misfit, Inc. #48,878 · 5 patents
- Mitsubishi Chemical Cleansui Corporation #48,880 · 5 patents
- MoMelan Technologies, Inc. #48,881 · 5 patents
- Mobi, LLC #48,882 · 5 patents
- Mobile Acuity Limited #48,883 · 5 patents
Leaders in C07D (Heterocyclic Compounds)
Other assignees with the most granted patents in Mitokinin's primary technology class.
Mitokinin's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
25 16th percentile higher than 16% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2019 | 1 | 20.0% |
| 2020 | 2 | 40.0% |
| 2022 | 2 | 40.0% |
Which technologies does Mitokinin, Inc. patent most?
Top 3 of 3 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Mitokinin, Inc.'s patent record in context - here's where to go next.
- Mitokinin, Inc.'s lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
- Ranked #48,793 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Mitokinin, Inc. against Miraculum, Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 24.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.